We are live on ! Find out more
REVB icon

Revelation Biosciences
REVB

2 hedge funds and large institutions have $589K invested in Revelation Biosciences in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

11.74% less ownership

Funds ownership: 21.34% → 9.61% (-12%)

50% less funds holding

Funds holding: 4 → 2 (-2)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

84% less capital invested

Capital invested by funds: $3.57M → $589K (-$2.98M)

Holders
2
Holders Change
-2
Holders Change %
-50%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$120K

Top Sellers

Rank Fund Capital Flow
1
MIM
Monashee Investment Management
Massachusetts
-$907K
2
Citigroup
Citigroup
New York
-$287K
3
BCM
Bridgeway Capital Management
Texas
-$135K
4
HF
HRT Financial
New York
-$12K
5
UBS Group
UBS Group
Switzerland
-$6K

REVB Hedge Fund Activity: Q3 2022 in Review

2 of the 5,830 institutional investors tracked by Wall St. Rank reported a position in Revelation Biosciences (REVB) for Q3 2022, worth a combined $589K — down 84% from $3.57M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of REVB and 1 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was State Street, opening a new position worth an estimated $120K. The largest seller was Monashee Investment Management, exiting entirely with an estimated $907K sold.

  • 2 institutional investors held Revelation Biosciences (REVB) as of Q3 2022, down from 4 in Q2 2022.
  • Funds reported $589K of Revelation Biosciences stock for Q3 2022, down 84% quarter-over-quarter.
  • 1 fund opened new Revelation Biosciences positions in Q3 2022 and 3 closed out, a net change of -2 holders.
  • The largest Revelation Biosciences buyer in Q3 2022 was State Street, an estimated $120K added.
  • The largest Revelation Biosciences seller in Q3 2022 was Monashee Investment Management, an estimated $907K sold.

Based on aggregated 13F filings for Q3 2022.